New insights into how a Phase III Alzheimer’s drug might work were among the advances in potential therapies targeting two brain proteins — amyloid and tau — recently reported. Scientists also reported on how clinicians view and treat mild cognitive impairment, a research category used to define the state between normal aging and Alzheimer’s, that is now being used widely in clinical practice.